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Background: Bimatoprost 0.01% was developed for improved tolerability over bimatoprost 
0.03%, while maintaining efficacy in lowering intraocular pressure (IOP). This multicenter, 
prospective, open-label, observational study was designed to investigate the efficacy and 
tolerability of bimatoprost 0.01% in routine clinical practice.
Methods: Data were collected from 10,337 patients with primary open-angle glaucoma or 
ocular hypertension attending 1334 centers in Germany. The primary efficacy outcome was 
mean change in IOP in each eye from baseline to 10–14 weeks after initiation of bimatoprost 
0.01%. Target IOP, prior therapies, additional treatments, and adverse events were also assessed. 
All treatment decisions were at the physicians’ discretion.
Results: Bimatoprost 0.01% significantly lowered mean IOP from baseline by −4.1 mmHg 
(P , 0.0001) in all patients after a mean of 10.45 weeks. In patients without previous treatment, 
bimatoprost 0.01% reduced mean IOP from baseline by −6.5 mmHg (P , 0.0001). Bimatoprost 
0.01% also significantly reduced IOP in patients previously treated with monotherapy of 
β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors or bimatoprost 0.03%. No 
adverse events were reported by 93.9% of patients during treatment with bimatoprost 0.01%; the 
most commonly reported adverse events were eye irritation (2.0%), ocular hyperemia (1.4%), 
and conjunctival hyperemia (1.2%). Physicians and patients rated tolerability and adherence as 
high, and most patients said they would continue with bimatoprost 0.01% treatment.
Conclusion: Bimatoprost 0.01% can produce additional IOP-lowering effects when used in 
routine clinical practice in patients who have received prior therapy, in addition to lowering IOP 
in previously untreated patients. A high rate of continuation of therapy with bimatoprost 0.01% 
was observed in patients who switched from a variety of different medications. The results sug-
gest that bimatoprost 0.01% is a suitable first-choice therapy in patients with primary open-angle 
glaucoma or ocular hypertension.
Keywords: bimatoprost 0.01%, glaucoma, observational, ocular hypertension, intraocular 
pressure
Introduction
Glaucoma is a leading cause of visual impairment, with 60 million people worldwide 
being affected and 8.4 million being bilaterally blind.1,2 Several risk factors for 
progressive loss of visual field in glaucoma have been identified, including abnormal 
baseline anticardiolipin antibody levels, older age, raised intraocular pressure (IOP), 
and female sex.3 However, IOP is currently the only modifiable risk factor for progres-
sion.4,5 Every 1 mmHg increase in IOP during follow-up is associated with a 10%–19% 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
739
ORiGiNAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S31330Clinical Ophthalmology 2012:6
increased risk of progression,3,4 and therefore lowering IOP 
can reduce progression.4,6 Consequently, medical treatments 
that lower IOP are considered first-line therapy for primary 
open-angle glaucoma and ocular hypertension.5
Two meta-analyses have shown that the prostaglandin 
derivative bimatoprost 0.03% (Lumigan® 0.03%) has greater 
overall ability to lower IOP than the prostaglandin analogs 
latanoprost (Xalatan®) and travoprost (Travatan®).7,8 A third 
meta-analysis reported that bimatoprost 0.03% and travoprost 
were both superior to latanoprost in IOP-lowering efficacy.9 
However, this analysis showed that tolerability was better with 
latanoprost than with bimatoprost 0.03%.9 The adverse event 
profile of bimatoprost 0.03% is typical of the prostaglandin 
analogs, with hyperemia, eye irritation, and increased eyelash 
growth among the commonly reported tolerability issues. 
These effects are mild in nature and the overall safety profile 
of bimatoprost 0.03% is good, according to a recent pooled 
analysis.10 However, any increase in tolerability of glaucoma 
medications is likely to lead to improved patient adherence.5,11 
A new formulation of bimatoprost (0.1 mg/mL; Lumigan 
0.01%) has been developed, and shows efficacy equivalent 
to that of bimatoprost 0.03%, with improved tolerability.12 
However, there are currently no published data on the use of 
bimatoprost 0.01% in routine clinical practice.
The objective of the present study was to investigate the 
use of bimatoprost 0.01% in clinical practice in Germany in a 
large number of patients with primary open-angle glaucoma 
or ocular hypertension. To our knowledge, this is the largest 
observational study of glaucoma treatment published to date, 
with over 10,000 patients recruited across several centers.
Methods
Participants
Patients were required to have a diagnosis of primary open-
angle glaucoma or ocular hypertension and to be already 
receiving treatment with bimatoprost 0.01%. Patients were 
eligible for inclusion regardless of whether they had previ-
ously received medical IOP-lowering therapy. Informed 
consent was obtained from all patients.
Study design
This was a multicenter, prospective, open-label, observational 
study designed to collect data on the use of bimatoprost 
0.01% in routine clinical practice. Patients were treated with 
bimatoprost 0.01% at a dose determined by their treating 
physician, and according to the prescribing information, 
which recommends that bimatoprost 0.01% is applied to 
the affected eye(s) as one drop once daily in the evening.13 
Other IOP-lowering therapies could be used in addition to 
bimatoprost 0.01% if required. Treatment decisions were at 
the sole discretion of the treating physician. Because this was 
a purely observational study in clinical practice, there was 
no washout period between treatments.
Two assessments were made per patient: a first at baseline 
and a second at weeks 10–14. The primary efficacy outcome 
was mean change in IOP (as assessed by tonometry) in 
each eye from baseline to the end of the study. Efficacy 
was also assessed in terms of target IOP; targets were set 
individually for each patient by their treating physician. Other 
study assessments included previous treatment, additional 
IOP-lowering medications, early study discontinuation and 
continuation of bimatoprost 0.01%, and physician-assessed 
and patient-assessed tolerability of bimatoprost 0.01%. 
Each investigator also assessed: number and percentage 
of patients with and without adverse events, frequency 
of adverse events by Medical Dictionary of Regulatory 
Activities preferred term, number and percentage of patients 
with ocular or conjunctival hyperemia, assessment of causal 
relationship between adverse event and bimatoprost 0.01% 
(definite, probable, possible, improbable, not assessable, not 
assessed, or no causal relationship), and occurrence of serious 
adverse drug reactions. Hyperemia was assessed by the 
treating physician as present or absent, and no standardized 
grading system was used. Compliance was recorded by 
the investigator as better, equal, worse, or not applicable 
compared with the prior therapy.
Statistical analysis
A target population of 15,000 patients from approximately 
3000 centers was planned for this study. This patient number 
allows the detection of uncommon adverse events with an 
incidence of .0.02% at least once (α = 0.05, binomial 
distribution). Data analysis was performed descriptively 
using SAS software (version 9.1; SAS Institute Inc, Cary, 
NC) and Medidata software (Medidata GmbH, Konstanz, 
Germany). Summary statistics included mean, standard 
deviation, median, minimum and maximum range, 
interquartile range, and frequency distribution tables, as 
appropriate for each item. Descriptive statistics were based 
on the safety population, defined as patients for whom any 
data were documented. All statistical analyses of efficacy 
were performed on patients with complete baseline IOP data. 
Change in IOP from baseline to visit 2 was analyzed using a 
two-sided paired t-test. Missing data were not replaced, unless 
the stop date of a medication was missing, in which case the 
respective medication was counted as ongoing.
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Results
Baseline demographics and patient 
disposition
The first patient was recruited to the study and underwent 
baseline monitoring in February 2010. Patient monitoring 
was completed in November 2010. A total of 10,337 patients 
were enrolled from 1334 participating centers or ophthal-
mologists in Germany.
The mean ± SD patient age was 67.3 ± 12.3 years, and 
58.1% of the 10,285 patients with information on sex were 
female. Most patients had a diagnosis of primary open-angle 
glaucoma (83.6%), and the remainder were diagnosed with 
ocular hypertension. Participant flow through the study is 
summarized in Figure 1. A total of 8817 patients (85.3%) 
remained on bimatoprost 0.01% throughout the study. There 
were 642 early discontinuations, of which 257 were due to 
unacceptable ocular tolerability and 202 were due to insuf-
ficient IOP control.
Bimatoprost treatment and additional 
therapies
Reasons for prescribing bimatoprost 0.01% were insufficient 
IOP control (52.6% of patients), poor tolerability (28.7%), 
evidence of glaucomatous disease progression (12.7%), or 
lack of compliance on prior treatment (7.9%). In the 9664 
patients for whom data were available, the mean ± SD duration 
of bimatoprost 0.01% therapy was 10.45 ± 5.94 weeks. At 
the end of the study, the dosage of bimatoprost 0.01% was 
one drop once daily for 96% of patients. Use of one or more 
additional IOP-lowering medications concomitantly with 
bimatoprost 0.01% was recorded for 1721 patients (16.6%). 
The most frequently occurring active ingredient in concomi-
tant IOP-lowering medications was timolol (62.1%), followed 
by brinzolamide (33.0%) and dorzolamide (28.1%); other 
active ingredients occurred with lower frequencies.
10,337 patients included (100%) 642*early discontinuations:
Patient decision to withdraw: 262
Unacceptable ocular tolerability: 257
Insufficient IOP control: 202
Missing data: 29
*Includes patients with multiple reasons
Other reason: 46
Lost to follow-up: 36
Physician’s decision to withdraw: 93
642 (6.2%) patients discontinued
8817 (85.3%) remained on bimatoprost 0.01%
throughout the study
878 (8.5%) missing data
•
•
•
•
•
•
•
Figure 1 Flow of participants through the study.
Abbreviation: iOP, intraocular pressure.
Table 1 Prior medications taken by .2% of patients, among 
those whose prior therapy was documented (n = 8441)a
Medication n % Active agent(s)
β-blockers
Tim-Ophtal® 789 9.3 Timolol (0.1%, 0.25%, 0.5%)
Timolol  
(not specified)
767 9.1 Timolol (0.1%, 0.25%, 0.5%)
TimoHexal® 242 2.9 Timolol (0.1%, 0.25%, 0.5%)
Timo-comod® 220 2.6 Timolol (0.25%, 0.5%)
NyoGel® 206 2.4 Timolol (0.1%)
Timomann® 199 2.4 Timolol (0.1%, 0.25%, 0.5%)
Betamann® 307 3.6 Metipranolol (0.1%, 0.3%, 0.6%)
Prostaglandin analogs
Xalatan® 1240 14.7 Latanoprost (0.005%)
Lumigan® 1008 11.9 Bimatoprost (0.03%)
Travatan® 690 8.2 Travoprost (0.004%)
Taflotan® 247 2.9 Tafluprost (0.0015%)
Carbonic anhydrase inhibitors
Azopt® 1120 13.3 Brinzolamide (1%)
Trusopt® 559 6.6 Dorzolamide (2%)
α2 adrenergic agonist
Alphagan® 384 4.5 Brimonidine (0.1%, 0.15%)
Clonid-Ophtal® 212 2.5 Clonidine (0.063%, 0.125%)
Fixed combinations
Cosopt® 712 8.4 Dorzolamide (0.2%), timolol (0.5%)
Azarga® 511 6.1 Brinzolamide (1%), timolol (0.5%)
Combigan® 230 2.7 Brimonidine (0.2%), timolol (0.5%)
Xalacom® 189 2.2 Latanoprost (0.005%), timolol (0.5%)
GANfort® 178 2.1 Bimatoprost (0.03%), timolol (0.5%)
Note: aSome patients previously received more than one iOP-lowering medication.
Abbreviation: iOP, intraocular pressure. 
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Prior therapies
Prior to switching to bimatoprost 0.01%, 81.7% of patients 
(8441/10,337) were recorded as having been previously 
treated with other IOP-lowering medications (Table 1). 
The remaining 1896 (18.3%) patients either had not been 
receiving prior IOP-lowering therapy or had no information 
available regarding previous therapy. Prior monotherapy was 
used in 54.7% of the total patient population (5654/10,337), 
while 18.6% of patients used two prior therapies, 6.1% 
used three prior therapies, and 2.2% used at least four prior 
therapies. The most frequent active ingredient in prior 
IOP-lowering therapies was timolol (4146/8441 = 49.1% 
of patients), followed by brinzolamide (18.6%), latanoprost 
(16.3%), dorzolamide (14.9%), bimatoprost 0.03% (13.8%), 
travoprost (9.8%), and brimonidine (9.0%). Other types of 
prior therapy were used at a frequency of less than 5%, such 
as tafluprost, which was used in 2.9% of patients.
Effect of bimatoprost 0.01% on iOP
In patients with complete data, the mean ± SD baseline 
IOP was 20.1 ± 4.5 mmHg in each eye. At visit 2, mean 
IOP in all patients with complete data was 16.0 mmHg 
in both eyes (reduction from baseline of −4.1 mmHg; 
P , 0.0001, Table 3), representing a 20.4% reduction in IOP 
from baseline (Figure 2).
Significant IOP reductions from baseline were observed 
in patients previously receiving monotherapy with β-blockers 
(–4.6 mmHg) or with the prostaglandin analogs latano-
prost (−2.8 mmHg), travoprost (–3.1 mmHg), tafluprost 
(−2.8 mmHg), or bimatoprost 0.03% (−1.0 mmHg; Table 3). 
Significant reductions in mean IOP were also observed in 
patients with complete data previously receiving the carbonic 
anhydrase inhibitors brinzolamide (n = 313, −4.4 mmHg; 
P , 0.0001) or dorzolamide (n = 181, −4.2 mmHg; 
P , 0.0001) as sole monotherapy. The largest IOP reduc-
tions occurred in patients who did not receive prior therapy 
(–6.5 mmHg; P , 0.0001, Table 3) where the IOP was 
reduced from baseline by 28.5%.
As stated by the physicians at the end of the monitoring 
period, target IOP was reached or exceeded in 70.3% of the 
study population, ranging from 63.9% in patients previously 
treated with latanoprost monotherapy to 80.0% in patients 
who previously received β-blocker monotherapy (Table 2). 
A similar percentage of patients reached target or lower IOP 
when previously treated with brinzolamide monotherapy 
(75.3%) or dorzolamide monotherapy (79.6%).
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Figure 2 Percentage reduction from baseline in mean iOP in all patients and in those receiving prior monotherapy (complete data) at 10–14 weeks following initiation of 
bimatoprost treatment. 
Abbreviation: iOP, intraocular pressure.
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Safety, tolerability, and compliance
Tolerability and compliance
Physicians rated the tolerability of bimatoprost 0.01% as 
very good or good in 92.6% of patients. Patients evaluated 
the tolerability of bimatoprost 0.01% as very good or good in 
89.3% of cases. According to the physicians, compliance was 
improved or unchanged, compared with previous therapy, in 
90.9% of previously treated patients. In total, 88.2% of all 
patients indicated that they wished to continue therapy with 
bimatoprost 0.01% beyond the end of the study.
Adverse events
The majority of patients (9708/10,337; 93.9%) did not 
report any adverse events during treatment with bimatoprost 
0.01%. The most commonly reported adverse events 
(.1% of patients) were eye irritation (2.0%), ocular hyperemia 
(1.4%), and conjunctival hyperemia (1.2%, Table 4). Ocular 
or conjunctival hyperemia occurred in 2.3% of patients 
(34/1449) previously treated with β-blocker monotherapy, 
2.3% of patients (10/444) previously treated with latanoprost 
monotherapy, 0.8% of patients (2/238) previously treated 
with travoprost monotherapy, no patients previously treated 
with tafluprost monotherapy (0/68), and 2.5% of patients 
(48/1896) without any prior treatment. Of the total 629 
adverse events reported, the investigators assessed 13.5% 
as being definitely related to bimatoprost 0.01% therapy, 
31.6% as probably related, 15.4% as possibly related, and 
the remainder as unlikely to be related.
Two patients experienced serious adverse drug reactions. 
The first was an acute exacerbation of chronic obstructive 
pulmonary disease with dyspnea in a patient who smoked 
and was diagnosed with ocular hypertension and chronic 
obstructive pulmonary disease. This was deemed prob-
ably related to study treatment. The episode resolved about 
14 days after oral prednisolone treatment was initiated. 
Bimatoprost 0.01% was discontinued and the patient was 
switched to brinzolamide 1%. The second serious adverse 
drug reaction was an asthma attack in a patient with bilateral 
glaucoma and asthma. This was deemed possibly related to 
study treatment. The patient recovered about 2 weeks after 
discontinuation of bimatoprost 0.01%.
Discussion
The aim of this large observational study was to examine 
the efficacy and tolerability of bimatoprost 0.01% in a rou-
tine clinical setting. Significant mean IOP reductions from 
baseline were observed in 10,337 patients with primary open-
angle glaucoma and ocular hypertension treated in Germany 
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Table 3 Baseline, final, and reduction from baseline in mean IOP (mmHg) in all patients and in those receiving prior monotherapy 
(complete data) at 10–14 weeks following initiation of bimatoprost treatment
n Baseline IOP 
(mmHg)
Final IOP 
(mmHg)
Change from baseline 
in IOP (mmHg)
P vs baseline
All patients
  Left eye 10,074 20.1 16.0 −4.1 ,0.0001
  Right eye 10,062 20.1 16.0 −4.1 ,0.0001
Prior monotherapy
β-blocker
  Left eye 1436 20.7 16.0 −4.6 ,0.0001
  Right eye 1437 20.7 16.0 −4.6 ,0.0001
Latanoprost
  Left eye 438 18.7 16.1 −2.6 ,0.0001
  Right eye 434 18.8 15.9 −2.9 ,0.0001
Travoprost
  Left eye 234 19.0 15.9 −3.1 ,0.0001
  Right eye 234 18.8 15.6 −3.2 ,0.0001
Tafluprost
  Left eye 63 18.4 15.7 −2.7 ,0.0001
  Right eye 63 18.6 15.8 −2.8 ,0.0001
Brinzolamide
  Left eye 313 19.7 15.3 −4.5 ,0.0001
  Right eye 313 19.6 15.4 −4.3 ,0.0001
Dorzolamide
  Left eye 181 19.6 15.5 −4.1 ,0.0001
  Right eye 181 19.8 15.5 −4.3 ,0.0001
Bimatoprost 0.03%
  Left eye 176 16.7 15.8 −0.9 ,0.0005
  Right eye 175 16.8 15.8 −1.0 ,0.0001
None
  Left eye 1825 22.8 16.3 −6.5 ,0.0001
  Right eye 1825 22.7 16.2 −6.5 ,0.0001
Abbreviation: iOP, intraocular pressure.
with bimatoprost 0.01% over a mean of 10.45 weeks. The 
great majority (81.7%) had previously received other IOP-
lowering therapies prior to using bimatoprost 0.01%, and the 
most common reason for switching to bimatoprost 0.01% was 
inadequate IOP lowering with previous therapy. This is in 
accordance with observations from a previous study, where 
the most common reason for change in ocular hypotensive 
medication was lack of IOP lowering, cited in 43% of patients 
in whom medication was changed.11
In this observational study, treatment with bimatoprost 
0.01% for a mean of 10.45 weeks was well tolerated, 
with 94% of patients experiencing no adverse events. The 
greatest reductions in IOP (−6.5 mmHg) from baseline 
were observed in patients without previous IOP-lowering 
therapy, in whom the baseline IOP was high (22.8 mmHg) 
compared with the other subgroups, as would be expected 
in untreated patients.   Significant reductions in IOP from 
baseline were also observed in patients who had previously 
been receiving monotherapy with β-blockers (–4.6 mmHg), 
latanoprost (−2.8 mmHg), travoprost (–3.1 mmHg), tafluprost 
(−2.8 mmHg), brinzolamide (–4.4 mmHg), dorzolamide 
(−4.2 mmHg), and bimatoprost 0.03% (−1.0 mmHg). The 
smallest reduction in IOP from baseline was observed in 
patients switched from bimatoprost 0.03% to bimatoprost 
0.01%, the subgroup of patients with the lowest recorded base-
line IOP (16.8 mmHg). In this case, the additional IOP lower-
ing achieved was probably due to increased compliance with 
bimatoprost 0.01% treatment, perhaps because of improved 
tolerability. Two meta-analyses have shown that bimatoprost 
0.03% has greater overall ability to lower IOP than latanoprost 
or travoprost.7,8 In the meta-analysis by Aptel et al,7 IOP reduc-
tion from baseline was significantly greater with bimatoprost 
0.03% at all time points measured (8 am, 12 pm, 4 pm, and 
8 pm) when compared with latanoprost, and at 8 am and 12 
pm when compared with travoprost. In this study, bimato-
prost 0.01% treatment provided greater efficacy in terms of 
IOP lowering in patients previously receiving latanoprost, 
travoprost, and tafluprost monotherapy.
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When tolerability was assessed in previous studies, the 
incidence of self-reported conjunctival hyperemia was higher 
with bimatoprost 0.03% than with latanoprost or travoprost.7 
The higher incidence of ocular hyperemia reported with 
bimatoprost 0.03% compared with latanoprost or travo-
prost prompted the development of bimatoprost 0.01%. In 
the 12-month study by Katz et al, bimatoprost 0.01% and 
0.03% had equivalent efficacy, which was sustained over 
the entire duration of the study, ie, bimatoprost 0.01% was 
noninferior to bimatoprost 0.03% in mean IOP change from 
baseline at all time points analyzed.12 Bimatoprost 0.01% was 
associated with a significantly lower incidence of treatment-
related ocular adverse events compared with bimatoprost 
0.03% (38.4 versus 50.8% of patients; P = 0.016).12 There 
was also an approximate 66% reduction in discontinuations 
due to treatment-related adverse events with bimatoprost 
0.01% versus bimatoprost 0.03%.12 In the current study, eye 
irritation was the most frequently reported adverse event, 
occurring in 2.0% of the total population. This is within the 
expected incidence range, given data from the Katz study, 
in which eye irritation occurred in 3.8% of patients receiv-
ing bimatoprost 0.01% and in 1.6% of patients receiving 
bimatoprost 0.03%.12 While follow-up was limited to 14 
weeks, the number of patients was large, and the incidence 
of many common adverse events of prostaglandin treatment 
(eg, eyelash growth and conjunctival hyperemia) decreased 
during long-term follow-up.14 This would suggest that our 
approach is unlikely to have missed many adverse events 
of significance.
Achievement of low levels of IOP slows the progression 
of glaucomatous optic neuropathy,4,6 and every mmHg 
increase in IOP during follow-up can equate to an increased 
risk of progression of 10%–19%.3,15 This observational study 
demonstrates that bimatoprost 0.01% can produce additional 
IOP-lowering effects when used in routine clinical practice 
in patients who have received prior therapy. Bimatoprost 
0.01% was also effective in previously untreated patients, 
suggesting its suitability as a first-choice drug for IOP 
lowering. European Glaucoma Society guidelines define 
first-choice treatment as a drug that a physician prefers as an 
initial IOP-lowering therapy.5 A first-choice therapy should 
be effective at lowering IOP while maintaining good patient 
tolerability and promoting patient adherence. Adherence in 
glaucoma is often overestimated by clinicians, and published 
measurements range from 5% to 80%.16 In the current study, 
a high rate of continuation of therapy was observed in 
patients who switched from a variety of different medications 
for a number of reasons, including poor tolerability and 
insufficient IOP lowering.
Although interpretation of our results is limited by the 
observational, noncontrolled, open-label nature and relatively 
short duration of the study, it provides a large body of data 
on the effects of bimatoprost 0.01% in clinical practice. The 
results suggest that bimatoprost 0.01% is a suitable first-
choice therapy in patients with primary open-angle glaucoma 
or ocular hypertension.
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